K562 Imatinib (Gleevec)-Resistant CML Model Service

The K562 Imatinib (Gleevec)-Resistant CML Model Service delivers a deeply characterized in vitro and in vivo system for studying acquired resistance to imatinib in chronic myeloid leukemia (CML). Alfa Cytology brings this model to clients as a complete preclinical offering—long-term, stepwise imatinib selection in suspension culture, systematic resistance-index and kinase-activity benchmarking, mutation and transporter profiling, and optional resistant xenograft or disseminated leukemia formats in immunodeficient mice—so that next-generation TKI and combination programs can proceed on a validated, publication-ready foundation.

Overview of K562 Imatinib (Gleevec)-Resistant CML Model

The K562 imatinib (Gleevec)-resistant CML model is built from K562, a human erythroleukemia cell line derived from a CML patient in blast crisis that carries the Philadelphia chromosome and constitutively expresses the BCR-ABL fusion tyrosine kinase. Because K562 is exquisitely dependent on BCR-ABL signaling for survival and proliferation, it is the canonical cellular background for studying imatinib, the first tyrosine kinase inhibitor (TKI) that revolutionized CML treatment. Under prolonged, progressively intensified imatinib exposure, surviving subclones emerge that no longer require effective BCR-ABL inhibition for growth, giving rise to resistant sublines documented in the literature under designations such as K562-R, K562r, K562/G01, and K562/IM-R. Reported resistance indices span roughly one to three orders of magnitude over the parental line, and several resistant variants also display reduced sensitivity to second-generation TKIs such as dasatinib and nilotinib, echoing the sequential TKI failure observed clinically.

Fig 1. ZFN-mediated bcr-abl disruption in the K562 imatinib-resistant model: apoptotic cell rates (Blank/pAd-Track/ZFN-L/ZFN-R/Donor/ZFN-L/R+Donor) reaching ~70% with ZFN-L/R+Donor in both K562 and K562/G01, DAPI morphology (arrows), PARP/caspase-3 Westerns, 5-day survival curves and clonogenic assays confirming loss of survival and colony formation in resistant cells. (Huang, Ningshu, et al., 2018)

What distinguishes imatinib resistance in K562 from classical multidrug resistance is the dominant role of the drug target itself. Resistant sublines commonly show kinase-domain point mutations in BCR-ABL—T315I is the most famous gatekeeper mutation, but E255K, Y253H, M351T, F317L, and F359V among others have been described—that impair imatinib binding or ATP-pocket occupancy, or alternatively BCR-ABL gene amplification and protein overexpression that outcompetes the inhibitor. Beyond these target-dependent routes, K562 imatinib resistance can also arise through BCR-ABL–independent mechanisms: overexpression of the efflux transporters P-glycoprotein (ABCB1) and BCRP (ABCG2), which actively pump imatinib out of cells; reduced intracellular drug uptake; activation of Src-family kinases such as LYN; and rebalanced apoptotic machinery, including Bcl-2/Bcl-xL elevation with BIM, BAX, and BAD down-regulation, alongside autophagy induction. This mechanistic diversity makes the model indispensable for benchmarking second- and third-generation TKIs, investigating synthetic lethality strategies, and evaluating HSP90 or HDAC inhibitor–based BCR-ABL degradation approaches in both cultured cells and immunodeficient-mouse formats.

Principles of K562 Imatinib (Gleevec)-Resistant CML Model Construction

Model construction applies chronic selective pressure with a targeted small-molecule inhibitor in suspension culture. K562 cells are exposed to imatinib in pulse cycles: each cycle begins at a concentration that permits only a minority of cells to survive, followed by drug-free recovery during which resistant survivors repopulate, and then an escalation to the next concentration level. Because K562 is BCR-ABL addicted, the surviving clones typically evade inhibition through kinase-domain mutations, gene amplification, or transporter-mediated drug exclusion, and repeated cycles drive these mechanisms to fixation. Selection is considered complete when the population grows with normal kinetics at a maintenance concentration that is lethal to the parental line, and stability is then verified after drug withdrawal.

Our Services

From the first low-dose exposure cycle through final quality-controlled release, Alfa Cytology supports the K562 imatinib-resistant CML model as a turnkey preclinical solution: clients receive authenticated resistant cell banks with quantified resistance indices, parallel parental controls, kinase-domain mutation and transporter profiling, and—when a whole-organism readout is needed—matched resistant xenograft or systemic leukemia cohorts, all documented in traceable study reports.

Workflow of K562 Imatinib (Gleevec)-Resistant CML Model Construction

Construction unfolds as a multi-month, cycle-based program tailored to suspension-cell biology and to the unique selection logic of a targeted inhibitor: escalation steps are small and frequent enough to capture rare resistant clones without collapsing the population, and every stage is checked against quantitative sensitivity benchmarks. Baseline characterization of the parental line precedes selection, and molecular confirmation follows phenotypic confirmation. The typical sequence includes the following steps:

1. Parental line qualification and baseline profiling: K562 cells are revived, authenticated, and mycoplasma-tested; baseline imatinib IC₅₀, doubling time, BCR-ABL transcript level, and baseline transporter expression are recorded as reference values.
2. Initiation of imatinib pulse cycles: Log-phase suspension cells are exposed to a low imatinib concentration (about 0.05–0.1 µM) for a defined window, after which surviving cells are washed by centrifugation and returned to drug-free complete medium for recovery.
3. Stepwise dose escalation: Once cultures regain steady proliferation, the imatinib concentration is raised by roughly 0.1 µM per cycle every 7–14 days, continuing for several months until the population grows robustly at a maintenance concentration of 1–2 µM or above.
4. Stabilization and drug-free rest: The resistant pool is maintained under selection pressure for extended passages, then cultured without imatinib for one to two weeks to verify that resistance is heritable and not an artifact of residual drug.
5. In vitro resistance confirmation. Dose–response curves for imatinib—and, where relevant, dasatinib and nilotinib—are generated by MTT/CCK-8 assay, and the resistance index is calculated against the parental baseline; clonogenic assays corroborate long-term survival.
6. Molecular and functional characterization: BCR-ABL kinase-domain sequencing, FISH/qPCR for fusion-gene copy number, phospho-CRKL and downstream STAT5/AKT/ERK signaling, P-gp/ABCG2 expression and imatinib accumulation assays, and apoptosis panel analysis map the resistance mechanism.
7. In vivo model establishment (optional stage). Validated resistant cells are inoculated either subcutaneously (typically 5 × 10⁶ cells per mouse) or via tail-vein injection (about 1 × 10⁶ cells) into immunodeficient mice to establish solid or disseminated resistant CML models.
8. Quality control and release: A release package is assembled covering authentication, mycoplasma status, passage history, resistance-index reports, molecular profiling results, and xenograft characterization before the model is delivered for study use.

Fig 2. K562 Imatinib (Gleevec)-Resistant CML Model Construction Workflow.

Case Study-K562 Imatinib (Gleevec)-Resistant CML Model Development

In a representative preclinical engagement, the Alfa Cytology team generated and characterized an imatinib-resistant K562 subline to support a client’s next-generation TKI evaluation program. Sustained stepwise selection produced a stable resistant population with a substantially elevated resistance index relative to parental cells, and molecular workup identified the principal resistance layer within the BCR-ABL axis alongside compensatory transporter activity. The validated subline was applied to comparative inhibitor profiling, and complementary xenograft studies were performed to place cellular findings in a whole-animal context. Engagement-specific datasets and study reports from this and similar programs are available upon request under confidentiality.

Why Choose Alfa Cytology?

Alfa Cytology unites targeted-therapy resistance expertise with disciplined, cycle-based suspension culture practice, ensuring that every K562 imatinib-resistant model is stable, well-documented, and immediately study-ready. Advantages of partnering with us include:

• Refined pulse–recovery selection methodology producing stable, heritable imatinib resistance.
• Systematic resistance-index benchmarking against matched parental controls with orthogonal assay confirmation.
• In-depth mechanism mapping spanning kinase-domain mutations, gene amplification, transporters, and apoptosis pathways.
• Integrated in vitro–in vivo options covering both subcutaneous and systemic CML formats.
• Complete traceability through authentication, mycoplasma screening, passage logs, and milestone-based reporting.
• Confidential, responsive project management aligned to TKI and combination-program timelines.

Contact Us

If your CML research program requires a validated imatinib-resistant model, we encourage you to reach out to us to discuss how the K562 imatinib (Gleevec)-resistant CML model can move your project forward. Contact the Alfa Cytology team today for a customized study plan, timeline, and quotation.

For research use only. Not intended for any clinical use.